Takeda strengthens cancer focus with Mersana ADC deal
This article was originally published in Scrip
Executive Summary
Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.